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Russ
• I always learned something new from friendly, smiling
Russ
• Most importantly, I learned that there is no substitute to
loving what you are doing
• There was no need to look for (other) giants in our field
of Pediatric Nephrology in general, and Mineral
Metabolism in particular, whenever Russ was around
• It is thus a real honor to be here today

Disclosure
•

Speaker for Ultragenyx

Overview
• The physiology of the players in mineral metabolism is
closely intertwined, with common final goals of:
(a) maintenance of mineral homeostasis
(b) in pediatrics - tissue buildup (bone and soft)
• The main minerals involved:
Calcium and phosphorus
• The main hormones regulating them:
Vitamin D, PTH and FGF23
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An example of possible aberration in vitamin D
metabolism: The role of 24-hydroxylase

Previously known as Idiopathic Infantile Hypercalcemia, loss of function of the
24-hydroxylase enzyme, caused by mutations in the CYP24A1 gene, will result in high 1,25(OH)2D blood level, and consequently hypercalcemia, hypercalciuria and nephrocalcinosis

A quick reminder of calcium homeostasis

PTH - the actual minute to minute regulator of
serum Ca++

Note the exceptional stability of Ca++ within a very narrow range

Effect of serum Ca++ on PTH

Note that minor changes in serum Ca++, well within its normal range,
result in significant changes in serum PTH

Ca sensor receptor (CaSR) - History
•

Brown EM et al.: Cloning and characterization of an
extracellular Ca(2+)-sensing receptor from bovine
parathyroid (Nature 1993;366:575)

•

Nemeth EF et al.: Calcimimetics with potent and
selective activity on the parathyroid calcium receptor
(Proc Natl Acad Sci USA 1998;95:4040)

CaSR Distribution

• Bone, cartilage, pituitary, placenta, intestine,
pancreas, calcitonin-producing cells
• Parathyroid glands
• Kidney

CaSR in the Parathyroid Glands
• When the CaSR is inactive (low serum Ca++), vesicles
move to the cell membrane and release their stores of
PTH. When the CaSR is activated by high serum Ca++
(or Mg ++ at 1/3 potency), the release of PTH is inhibited.

Roles of CaSR and VDR in the parathyroid glands

Note the role of CaSR in gland proliferation, a common problem in the CKD population

CaSR in the kidney (1)
• The CaSR is most abundant in the basolateral cell
surface of the cortical thick ascending limb of the loop of
Henle (cTAL) (but is present also in most other tubular segments)

CaSR in cTAL

CaSR in the kidney (2)
• In the cTAL, CaSR activation inhibits the activity of
Na/K2Cl co-transporters and, consequently, sodium
reabsorption
• This leads to decrease in lumen-positive transepithelial
voltage and consequently to decrease in passive,
paracellular Ca (+Mg) reabsorption, resulting in  in
calciuria (& magesuria)
• It is therefore of clinical relevance, when using
calcimimetics (thus stimulating the CaSR), to monitor for
hypercalciuria (amenable to thiazide diuretics)

Rickets – a disease of phosphate insufficiency
• The common denominator of all types of rickets is
hypophosphatemia (leaving aside bone disease in CKD)
• Hypophosphatemia prevents apoptosis of mature
chondrocytes at the growth plate, and consequently the
chain of events that includes invasion of blood vessels
and generation and mineralization of new bone
• Elevated alkaline phosphatase activity, seen in all cases
of rickets, is an indicator of activity of osteoblasts, trying
to recruit phosphate, for the formation of hydroxyapatite,
by breaking down pyrophosphate

Differential Diagnosis of Rickets Based on Serum PTH

Note that serum P is always low, either due to high PTH or abnormalities in P metabolism

Hereditary vitamin D resistant rickets
(HVDRR): PTH and calcimimetics (1)
• HVDRR is a rare autosomal recessive disorder which
results from loss of function mutation in vitamin D
receptor (VDR) gene, leading to target organ resistance
to 1,25(OH)2-D
• It presents in early life with hypocalcemic tetany and
rickets
• Biochemically serum Ca and P are low, and 1,25(OH)2-D
and PTH are very high
• Traditional treatment: high doses of calcium, provided IV
in infancy (20/24 hours daily) and PO later in life

Vitamin D resistant rickets:
PTH and calcimimetics (2)
• We speculated that the rickets is the result of low serum
phosphate resulting from the excessive phosphaturic
effect of high serum PTH

• As such (and after treatment with IV calcium became life
threatening, due to recurrent infections of the central line), in order
to suppress PTH secretion, we applied cinacalcet

Treatment of a child with HVDRR:
IV calcium (Period II) followed by Cinacalcet (Period iV)

PTH ______, Alk Phosph --------

Treatment of a child with HVDRR:
IV calcium (Period II) followed by Cinacalcet (Period IV)

Note the increase in serum P (----) as PTH was suppressed
by either IV calcium (Period II), or cinacalcet (Period IV)

Period I: Age 15 months (left) and 19 months (right)

Period II: Age 22 months (left) and 27 months (right)

Period III: Age 36 months (left) and 42 months (right)

Period IV: Age 57 months (left) and 70 months (right)

Differential Diagnosis of Rickets Based on Serum PTH

X-linked (dominant) hypophosphatemic rickets
•

•

•

The most common inherited rickets caused by mutations in the
PHEX gene, leading to elevated serum levels of FGF23, and
consequently suppression of proximal tubule P reabsorption and
1,25 (OH)2D production, resulting in hypophosphatemia and rickets
Traditional treatment includes calcitriol and high repetitive doses of
oral phosphate
However, complications are frequent and include nephrocalcinosis
and secondary hyperparathyroidism, at times progressing to tertiary
hyperparathyroidism and damage to the kidneys to the point of
ESKD

FGF23-blocking Agents
• The development of a human antibody to FGF23 opened
a new field of treatment of XLH
• Indeed studies showed that a SQ injection, q2W, in
children with XLH, resulted in normalization of TP/GFR,
serum phosphate and 1,25 (OH)2-D levels, and healing
of rickets, with no adverse effects
•

Interestingly in my patient, following treatment serum FGF23 went
up from 230 to 99,500 RU/ml

• Will the medication have a place in our ESKD population
(protecting their hearts)?

Grandpa, Dad, Grandkids and Cessna 206 are ready to go flying

Thanks for your attention

